Modulation of FVIII immunogenicity by truncated VWF
AssigneeCsl Behring Lengnau AG
InventorsAnne Verhagen, Sabine Pestel, Thomas Weimer, Marco Hofmann, Huy Huynh, Eugene Maraskovsky
Life of this patent
Estimating the term…
Abstract
The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
Claims20
A method for treating a subject suffering from a blood coagulation disorder, comprising co-administering to the subject:
- (a) a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII);
- and
- (b) an FVIII protein,
- wherein the recombinant polypeptide comprises at least one amino acid substitution chosen from S764P/S766W/V1083A, S764G/S766Y/V1083A, S764E/S766Y/V1083A, N1011S/V1083A/K1181E, S766Y/V1083A, V1083A, S1042T, V805A/Q1158L, and K912E/T1088S, compared to SEQ ID NO:4, and
- wherein the recombinant polypeptide reduces the immunogenicity of FVIII.
Dependencies are inferred from the claim text.